Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- NBI to Establish Holding Company
June 14, 2010
- CROee Ties Up with BBK for Recruitment of Subjects
June 14, 2010
- Industry Expects New Gov't Will Retain Industrial Policy
June 14, 2010
- Japanese Drugs Regarded as Reliable in China: Mr Matsubara
June 14, 2010
- Avastin Effective for Ovarian Cancer: ASCO 2010
June 14, 2010
- Gov't to Intensively Invest in Selected Fields
June 14, 2010
- Merger with Wyeth Puts Pfizer Closer to Top Place in Japan
June 14, 2010
- Tsumura: Record-High Profits Driven by Kampo Medicines
June 14, 2010
- Eribulin Prolongs OS in Breast Cancer Patients: ASCO
June 14, 2010
- METI's Council Calls For 5% Reduction in Corporate Tax
June 14, 2010
- Sales of 23 Domestic JPMA Member Companies Up 4.3%
June 14, 2010
- Nissui Pharm.: Profits Up Due to Profit Structure Reform
June 14, 2010
- Terumo: Sales Up 4.4% to ¥316 Bil.
June 14, 2010
- FDA Accepts NDA for Eisai's AcipHex Extended-Release
June 14, 2010
- Sales of 26 Member Companies Up 2.0%: JPMA
June 14, 2010
- Biofermin: Sales Down 1.0% to ¥8,455 Mil.
June 14, 2010
- Nipro: Drugs Make Up for Decline in Sales of Med. Devices
June 14, 2010
- Amgen Submits BLA for Denosumab for Bone Metastases in the US
June 14, 2010
- Takeda to Enhance Presence in Lifestyle-Related Disease Area
June 14, 2010
- Kobayashi Pharm.: Net Profits Up for 12th Straight Year
June 14, 2010
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…